Thermo Fisher Scientific has announced that BRI Biopharmaceutical Research has selected the Watson laboratory information management system (Lims) to manage bio-analytical and analytical data.
This includes LC/MS/MS assays of specialised biomarkers, nucleotides, peptides and synthetic small molecule drugs in support of GLP PK/TK pre-clinical studies and clinical phase I to IV trials.
Watson Lims is a highly specialised, protocol-driven Lims for drug metabolism and pharmacokinetic (DMPK) studies.
Watson Lims will also be used to manage BRI's in vivo and in vitro DM/PK/ADME studies.
BRI Biopharmaceutical Research has standardised on Watson Lims across its facilities in Canada.
The company supports drug discovery and development by offering a range of services that help clients reduce the time it takes to bring new drugs to market.
The addition of Thermo Scientific Watson Lims to BRI's facilities will ensure timely delivery of quality results to clients and improve the internal operational efficiency and profitability of the company.
